Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial

• Published in: Lung cancer (Amsterdam, Netherlands) Netherlands), 1995-12, Vol.13 (3), p.295-303
• Main Authors: Vansteenkiste, J., Vandebroek, J., Mariën, S., Roex, L., Bertrand, P., Bockaert, J., De Beukelaar, T., Deman, R., De Muynck, P., Ulrichts, H., Van Kerckhoven, W., Verhelst, F., Verschuere, J., Verstraete, A., Demedts, M.
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - drug therapy; Adult; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carcinoma, Large Cell - drug therapy; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Squamous Cell - drug therapy; Chemotherapy; Chi-Square Distribution; Cisplatin; Cisplatin - administration & dosage; Cisplatin - adverse effects; Cisplatin - therapeutic use; Confidence Intervals; Female; Humans; Ifosfamide; Ifosfamide - administration & dosage; Ifosfamide - adverse effects; Ifosfamide - therapeutic use; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Medical sciences; Middle Aged; Neoplasm Staging; Non-small cell lung cancer; Pharmacology. Drug treatments; Prospective Studies; Survival Rate; Time Factors; Vindesine; Vindesine - administration & dosage; Vindesine - adverse effects; Vindesine - therapeutic use; Weight Loss
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/0169-5002(95)00502-1

The efficacy and toxicity of a regimen adding ifosfamide to the more classical cisplatin-vindesine combination was studied in patients with advanced non-small cell lung cancer. Sixty-four good performance patients with inoperable stage III or stage IV were treated with VIP: vindesine 3 mg/m 2 days 1 and 8, ifosfamide 1200 mg/m 2 and platinum 30 mg/m 2 days 1, 2 and 3, repeated every 4 weeks, up to a maximum of six cycles. Response rate, clinical data and radiological tests were rigourously reviewed by a panel. Overall response rate was 39% (95% confidence interval, 27%–51%) with three patients achieving a complete response; response rate in stage III was 48%. Median survival was 9 months. Toxicity consisted mainly of bone marrow toxicity and nausea/vomiting, but was manageable. There was no renal toxicity greater than grade 2, four severe infections, but no treatment-related deaths. Conclusion: VIP as mentioned above is very active in good performance patients with advanced non-small cell lung cancer. Its activity, together with its manageable toxicity—without severe renal or pulmonary toxicity—makes it an attractive candidate for induction chemotherapy.